Medvi’s AI-Driven Telehealth Empire Built on Dubious Doctor Ads and Regulatory Red Flags

In a rapidly expanding but increasingly scrutinized sector, AI-powered telehealth startup Medvi has grown into a billion-dollar enterprise by leveraging affiliate marketing networks that often feature doctors who don’t exist. The New York Times estimates the company’s 2024 revenue at $401 million, with projected sales of $1.8 billion this year. Yet behind its explosive growth lies a web of regulatory concerns, consumer lawsuits, and deceptive advertising practices that have drawn the attention of the Federal Trade Commission (FTC) and the U.S. Food and Drug Administration (FDA). At the heart of the controversy is Medvi’s use of AI-generated marketing materials and affiliate marketers who, in some cases, appear to have fabricated medical professionals to promote weight-loss drugs and other prescription treatments—practices that raise serious questions about patient safety, regulatory compliance, and the integrity of digital health advertising.

• Medvi, an AI-driven telehealth startup, generated $401 million in 2024 and is projected to reach $1.8 billion in sales in 2025.
• The company has faced multiple lawsuits and regulatory warnings over allegedly fake doctors used in ads and deceptive marketing practices.
• Founder Matthew Gallagher admitted that up to 30% of Medvi’s advertising came from affiliate marketers, some of whom used AI-generated content.
• The FDA and FTC have issued warnings about Medvi’s claims, including misleading comparisons to FDA-approved drugs like Wegovy.
• Medvi disputes allegations, stating it enforces a 'no spam' policy and investigates affiliate misconduct.

How Medvi’s AI-Powered Model Amplified Growth—and Red Flags

Medvi’s rise is a case study in the dual-edged promise of artificial intelligence in healthcare. Founded by Matthew Gallagher, a serial entrepreneur with a background in digital marketing, the company has built its operations around automation, using AI tools such as ChatGPT, Claude, and Grok to construct its website, generate customer communications, and even populate product descriptions. Gallagher’s initial investment of $20,000 in AI software and marketing in the company’s first month underscored a strategy rooted in scalability and low overhead. Today, Medvi employs just two people, relying instead on a vast network of third-party contractors and affiliate marketers to drive customer acquisition.

This model has delivered explosive financial results: according to internal projections cited by the New York Times, Medvi is on track to surpass $1 billion in annual sales. However, the company’s reliance on external partners for marketing has introduced significant risks. Gallagher disclosed to Business Insider that roughly 30% of Medvi’s advertising spend flows through affiliates—often unvetted intermediaries who operate with varying degrees of transparency. While Gallagher emphasized that Medvi maintains a ‘clear policy’ requiring disclosure of AI-generated actors or non-existent medical professionals, an investigation by Business Insider found numerous instances where such disclosures were absent.

AI-Generated Doctors and the Illusion of Credibility

A review of Meta’s Ad Library in late 2024 revealed dozens of ads featuring profiles of doctors who appear to be entirely fabricated. One such profile, ‘Dr. Matthew Anderson MD,’ listed an Angolan phone number and contained a profile photo that, upon closer inspection, exhibited signs of AI generation—garbled text and unnatural features. Notably, the page’s ‘About’ section suggested it had once belonged to a gospel musician, raising questions about identity theft or reuse of old accounts. Another profile, ‘Dr. Spencer Langford MD,’ included posts and contact information linked to a clothing store in the Republic of Congo, further undermining claims of legitimacy.

Perhaps most egregiously, the same profile photo was reused across multiple pages advertising Medvi’s services. One account, originally named ‘Wade Frazer MD,’ removed the ‘MD’ credential after being contacted by Business Insider. The use of such tactics—particularly the portrayal of non-existent medical professionals—violates FTC guidelines, which require advertisers to ensure their claims are truthful and not misleading. The FTC has explicitly warned that health-related marketing demands heightened scrutiny, as consumers are especially vulnerable to deceptive claims about safety, efficacy, and regulatory approval.

‘In line with the FTC, we have a clear policy of providing disclosure on any actor or AI portrayal of a doctor or not using them at all,’ Matthew Gallagher told Business Insider. ‘If we find an affiliate doing this we work to take these ads down.’

Yet despite these assurances, Business Insider’s review found that none of the pages in question included prominent disclosures about the use of AI or non-existent doctors. This pattern of non-compliance has not gone unnoticed by consumer advocacy groups, which have escalated their calls for regulatory intervention.

Regulatory Warnings and Consumer Advocacy: Why Medvi Is in the Crosshairs

Medvi’s aggressive marketing tactics have drawn the ire of the National Consumers League (NCL) and other advocacy organizations, which in September 2024 sent a formal request to the FTC for an investigation into the company and five other telehealth firms. The NCL’s director of food, nutrition, and obesity, Nancy Glick, argued that Medvi’s use of phrases like ‘trusted by experts’ and ‘doctor-approved’ on its website misleads consumers about the safety and testing of the compounded drugs it sells—a critical concern given the rapid proliferation of online telehealth providers selling unregulated compounded medications.

Glick told Business Insider that Medvi’s practices violate the FTC Act, which prohibits deceptive advertising. ‘What Medvi is doing violates the FTC Act,’ she said. ‘With so many companies selling compounded drugs online, it’s like playing a game of whack-a-mole.’ Compounded drugs, which are not subject to the same FDA approval process as brand-name medications, have become a flashpoint in the telehealth industry, particularly as GLP-1 weight-loss drugs like Wegovy and Zepbound dominate the market. Consumers seeking access to these medications are often lured by promises of rapid approval and lower costs, only to find themselves purchasing untested or misbranded alternatives.

FDA Cracks Down on Misleading Claims

The FDA has also taken aim at Medvi’s marketing practices. In February 2024, the agency sent a warning letter to medvi.io—a domain Gallagher later claimed was operated by an affiliate without permission—alleging that the site made ‘false or misleading’ claims. These included comparisons to FDA-approved drugs like Wegovy and images suggesting that Medvi itself compounded the medications it sells. Gallagher disputed the FDA’s characterization, stating that the website in question was not owned or operated by Medvi and had been taken down by the affiliate after the FDA’s intervention. However, the incident underscores broader concerns about transparency and accountability in the digital health space.

Legal Troubles Mount: Spam Lawsuits and Mounting Scrutiny

Medvi’s marketing practices have not only triggered regulatory scrutiny but also legal action. Since late 2023, the company has been named in at least three lawsuits alleging violations of spam laws, including the sending of unsolicited text messages and emails. One of these lawsuits has since been dropped, while two others remain pending. In response to the allegations, Medvi has maintained that it adheres to a ‘strict no spam policy’ and only communicates with opted-in recipients. Gallagher stated that the company investigates any claims of affiliate misconduct and takes ‘immediate action’ to address violations.

In a legal filing responding to one of the lawsuits, Medvi denied engaging in any illegal conduct in any jurisdiction. Yet the lawsuits highlight a recurring issue in the telehealth industry: the challenge of monitoring and controlling the behavior of third-party affiliates who may prioritize sales over compliance. This dynamic has drawn comparisons to past controversies involving other digital health companies, such as Cerebral, a mental health startup that paid millions in 2024 to settle a federal investigation into allegations of overprescribing medications like Adderall to patients who did not need them.

The Broader Telehealth Landscape: Growth, Risks, and Regulatory Gaps

Medvi’s story is emblematic of the telehealth sector’s explosive growth—and the growing pains it has encountered since the COVID-19 pandemic. According to industry data, the percentage of doctors seeing patients virtually remains nearly triple what it was before 2020, even as the initial surge in demand has stabilized. The pandemic accelerated adoption of telehealth services, particularly for treatments like ADHD medications and GLP-1 weight-loss drugs, which saw surging demand amid supply shortages and high costs of brand-name alternatives.

Yet the industry’s rapid expansion has outpaced regulatory oversight, leaving gaps that unscrupulous actors have exploited. The Federal Trade Commission has warned that health-related marketing—especially for prescription drugs—requires ‘more supervision’ than lower-risk sectors like fashion. Companies that fail to monitor their affiliates risk running afoul of consumer protection laws, as Medvi’s case illustrates. ‘They really would need an army just to be able to find these offenders,’ Glick of the NCL said, underscoring the enormity of the challenge facing regulators.

What’s Next for Medvi and the Telehealth Industry?

As Medvi navigates mounting legal and regulatory challenges, the company’s future hinges on whether it can reconcile its AI-driven efficiency with the need for transparency and compliance. Gallagher’s reliance on affiliate marketing—a common strategy in digital advertising—has proven effective in driving growth but has also exposed the company to significant reputational and legal risks. The FTC’s ongoing scrutiny, coupled with the FDA’s warning letter, suggests that the agency is prepared to take action against companies that prioritize sales over patient safety.

For consumers, the Medvi saga serves as a cautionary tale about the promises and pitfalls of telehealth. While AI and digital platforms have democratized access to medical care, they have also created new avenues for deception and exploitation. The proliferation of compounded weight-loss drugs, in particular, highlights the need for clearer regulations and stronger enforcement to protect vulnerable patients from misleading claims and unproven treatments.

A Timeline of Medvi’s Controversies and Regulatory Responses

• 2023: Medvi launches with AI-driven marketing and affiliate-heavy growth model.
• February 2024: FDA issues warning letter to medvi.io for false or misleading claims about compounded drugs.
• May 2024: Futurism reports on Medvi’s use of AI-generated doctors in ads.
• September 2024: National Consumers League and other groups request FTC investigation into Medvi and five other telehealth companies.
• Late 2024: Business Insider uncovers multiple allegedly fake doctor profiles in Medvi’s ads; number of active campaigns drops from over 5,000 to 2,800 after inquiry.
• December 2024: Medvi faces at least three lawsuits alleging spam violations; two remain pending.